Full-Time

Health Outcomes Liaison/Senior Health Outcomes Liaison

Field Medical Affairs

Confirmed live in the last 24 hours

Axsome Therapeutics Inc

Axsome Therapeutics Inc

201-500 employees

Develops therapies for central nervous system disorders

Biotechnology
Healthcare

Compensation Overview

$170k - $205kAnnually

+ Annual Bonus + Equity

Senior

Los Angeles, CA, USA

Field-based role in Los Angeles, CA.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • PhD, PharmD, MD, or DO preferred. Candidates with a Master’s degree and significant relevant experience will also be considered
  • A minimum of 5 years of experience in a field based managed care, health outcomes role, or a hybrid HOL/payer role, or has a combination of industry & other payer related experience
  • Health outcomes, pharmaco-economics, population-based health management knowledge
Responsibilities
  • Communicate the clinical, economic, and humanistic value proposition of Axsome’s portfolio of products, in a fair and balanced manner, using approved resources, to healthcare population health decision makers including Pharmacy Directors, Medical Directors, Case Managers, Clinical Pharmacists, Formulary Decision Makers, etc. within payer organizations and to managed care professionals to ensure access to Axsome medications and improve patient outcomes
  • Collaborate closely with HEOR Strategy team, market access and other internal teams in development and execution of field-based tools
  • Compliantly coordinate activities with market access field team to ensure compliant and aligned account support
  • Identify opportunities to work with payers, academic institutions, and individuals to discuss research and facilitate initiation of HEOR research and evidence gap studies as aligned with strategy
  • Demonstrate leadership in area of evidence-based medicine and provide training and information to Field Medical and other functions as requested
  • Attend and provide support at relevant national and regional conferences throughout the year
  • Exchange information with population health decision makers and collect, synthesize and communicate actionable insights to internal stakeholders in order to help shape strategy and tactics
  • Be a Field therapeutic area expert demonstrating high scientific knowledge and competency in relevant therapeutic areas
Desired Qualifications
  • Experience working in CNS Therapeutic areas preferred
  • Strong knowledge of health economics outcomes research methodologies, and health policy
  • Experience with Payors, IDNs, GPOs and Government Programs preferred
  • Demonstrates in-depth understanding of the US Healthcare system and healthcare policy
Axsome Therapeutics Inc

Axsome Therapeutics Inc

View

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received FDA Breakthrough Therapy Designation, allowing for faster development and review. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous clinical trials and regulatory approvals. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

Company Stage

IPO

Total Funding

$430.7M

Headquarters

New York City, New York

Founded

2012

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA's fast-tracking of CNS treatments could expedite Axsome's drug approvals.
  • Increased investment in CNS R&D drives innovation, benefiting Axsome's pipeline.
  • Growing personalized medicine trend offers Axsome opportunities for tailored therapies.

What critics are saying

  • Increased competition from companies like Compass Pathways in the CNS market.
  • Potential delays in AXS-07 launch amid growing market anticipation.
  • Departure of key personnel like Lori Englebert may impact strategic direction.

What makes Axsome Therapeutics Inc unique

  • Axsome focuses on CNS disorders with limited current treatment options.
  • AXS-05, an NMDA receptor antagonist, targets major depressive disorder and treatment-resistant depression.
  • Axsome's balanced portfolio includes both clinical and research stage products.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company Equity